

# GELUSIL-S

## SCHEDULING STATUS:

S0

## PROPRIETARY NAME (AND DOSAGE FORM):

Gelusil-S (tablet)

## COMPOSITION:

Each tablet contains:

Aluminium Hydroxide Dried Gel	200 mg
Magnesium Hydroxide	200 mg
Simethicone (activated methylpolysiloxane)	20 mg

(Magnesium content: 3,4 mmol per tablet)

## PHARMACOLOGICAL CLASSIFICATION:

A: 11.4.1 Antacids - Acid neutralisers.

## PHARMACOLOGICAL ACTION:

Gelusil-S is a combination of two antacids, aluminium hydroxide and magnesium hydroxide plus a defoaming agent, simethicone. This component breaks down barriers of foaming mucus thereby providing effective anti-flatulent action.

## INDICATIONS:

For the relief of hyperacidity and flatulence associated with heartburn, gastritis and acid indigestion, and as adjunctive treatment in peptic ulcers.

## CONTRA-INDICATIONS:

Sensitivity to any of the ingredients. Impaired renal function.

## DOSAGE AND DIRECTIONS FOR USE:

### Adults:

One or two tablets chewed or allowed to disintegrate in the mouth 4 to 8 times a day, preferably between meals, or as directed by a doctor. Do not take more than 16 tablets in a 24 hour period.

Do not use the maximum dosage of this product for more than 2 weeks, except under the advice or supervision of a doctor.

## SIDE-EFFECTS AND SPECIAL PRECAUTIONS:

Aluminium hydroxide may cause nausea, vomiting and constipation. Large doses can cause intestinal obstruction. Aluminium hydroxide in patients with low-phosphate diets may lead to phosphate depletion accompanied by increased resorption and urinary excretion of calcium with the risk of osteomalacia. Osteomalacia, and also encephalopathy and dementia, have occurred in patients with chronic renal failure who received relatively high doses of aluminium hydroxide as a phosphate-binding agent.

Magnesium may cause diarrhoea. Although magnesium is poorly absorbed following oral administration, hypermagnesaemia has occurred after the excessive use of magnesium-containing

antacids and especially in renal insufficiency. Symptoms may include flushing of the skin, thirst, hypotension due to peripheral vasodilatation, drowsiness, confusion, loss of tendon reflexes due to neuromuscular blockade, muscle weakness, respiratory depression, cardiac arrhythmias, coma, and cardiac arrest.

**Interactions:**

**Gelusil-S** used concurrently with oral tetracyclines, digoxin, oral iron preparations, anticholinergic drugs, barbiturates, quinines, quinidine, warfarin, vitamins, H<sub>2</sub>-receptor antagonists, oral isoniazid, sucralfate, sodium fluoride, ketoconazole, phenytoin, phenothiazines and methenamine may reduce the absorption of these agents.

In general, patients should be advised not to take any oral medication within at least 2 hours of taking antacids.

**KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:**

See Side-effects and Special precautions.

Treatment: Symptomatic and supportive.

**IDENTIFICATION:**

A white, round, bevel-edged tablet with a lemon-spearmint odour and taste.

**PRESENTATION:**

Blisters of 16 and 24 tablets.

**STORAGE INSTRUCTIONS:**

Store in a cool (below 25°C), dry place. KEEP OUT OF REACH OF CHILDREN.

**REGISTRATION NUMBER:**

E/11.4.1/633

**NAME AND BUSINESS ADDRESS OF APPLICANT:**

Pharma Dynamics (Pty) Ltd.  
F02 Grapevine House,  
Steenberg Office Park,  
Westlake,  
7945

**DATE OF PUBLICATION OF THIS PACKAGE INSERT:**

24 March 1993.

# GELUSIL-S

## SKEDULERINGSSTATUS:

S0

## EIENDOMSNAAM (EN DOSERING VORM):

Gelusil-S (tablet)

## SAMESTELLING:

Elke tablet bevat:

Gedroogde Aluminiumhidroksiedjel	200 mg
Magnesiumhidroksied	200 mg
Simetikoon (geaktiveerde metielpolisiloksaan)	20 mg

(Magnesium inhoud: 3,4 mmol per tablet)

## FARMAKOLOGIESE KLASSIFIKASIE:

A: 11.4.1 Teensure - Suurneutraliseerders.

## FARMAKOLOGIESE WERKING:

Gelusil-S is 'n kombinasie van twee teensuurmiddels, aluminiumhidroksied en magnesiumhidroksied tesame met 'n teenskuimmiddel, simetikoon. Hierdie komponent breek skuimskanse van slym af, met gevolglike effektiewe werking teen winderigheid.

## INDIKASIES:

Vir die verligting van oormatige suur en opgeblasenheid geassosieer met sooibrand, gastritis en slegte spysvertering, en as bykomstige behandeling by peptiese ulkuse.

## KONTRA-INDIKASIES:

Sensitiwiteit vir enige van die bestanddele. Beskadigde nierfunksie.

## DOSIS EN GEBRUIKSAANWYSINGS:

### Volwassenes:

Een of twee tablette gekou of opgelos in die mond 4 tot 8 maal per dag, verkieslik tussen maaltye, of soos voorgeskryf deur 'n geneesheer. Moet nie meer as 16 tablette in 'n 24 uur periode inneem nie.

Moet nie die maksimum dosis van hierdie produk vir meer as 2 weke gebruik nie, behalwe op aanbeveling of onder toesig van 'n geneesheer.

## NEWE-EFFEKTE EN SPESIALE VOORSORGMAATREëLS:

Aluminiumhidroksied kan naarheid, vomering en konstipasie veroorsaak. Groot dosisse kan intestinale obstruksie veroorsaak. By pasiënte wat op laefosfaatdiëte is, kan aluminium lei tot fosfaatuitputting wat met verhoogde resorpsie en urinêre uitskeiding van kalsium gepaard gaan, en die risiko van osteomalasie. Osteomalasie, sowel as enkefalopatie en demensie, het al voorgekom in pasiënte met chroniese nierversaking wat relatief hoë dosisse aluminiumhidroksied as 'n fosfaatbinder ontvang het.

Magnesium kan diaree veroorsaak. Alhoewel die absorpsie van magnesium na mondelike toediening swak is, het hipermagnesemie al na oormatige gebruik van teensuurmiddels wat

magnesium bevat, en veral in die geval van renale ontoereiktheid, voorgekom. Simptome kan velgloede, dors, hipotensie weens perifere vasodilasie, lomerigheid, verwarring, verlies van tendonreflekse as gevolg van neuromuskulêre versperring, spierswakheid, respiratoriese onderdrukking, kardiale aritmies, koma en kardiale arres insluit.

**Interaksies:**

Gelyktydige gebruik van Gelusil-S met mondelike tetrasiklene, digoksien, mondelike ysterpreparate, anticholinergiese geneesmiddels, barbiturate, kinien, kinidien, warfarien, vitamien, H<sub>2</sub>-reseptor-antagoniste, mondelike isoniasied, sukralfaat, natriumfluoried, ketokonasool, fenitoïen, fenotiasiene en metenamien kan die absorpsie van hierdie middels verminder.

In die algemeen behoort pasiënte aangeraai te word om geen ander mondelike medikasie binne minstens 2 ure nadat teensure gebruik is, in te neem nie.

**BEKENDE SIMPTOME VAN OORDOSERING EN BESONDERHEDE VAN DIE BEHANDELING DAARVAN:**

Sien Newe-effekte en Spesiale voorsorgmaatreëls.

Behandeling: Simptomaties en ondersteunend.

**IDENTIFIKASIE:**

'n Wit, rond, afgeskuinste tablet met 'n suurlemoen-groenmentgeur en -smaak.

**AANBIEDING:**

Stulpverpakkings met 16 en 24 tablette.

**BERGINGSINSTRUKSIES:**

Bewaar op 'n koel (benede 25°C), droë plek. HOU BUIITE BEREIK VAN KINDERS.

**REGISTRASIENOMMER:**

E/11.4.1/633

**NAAM EN BESIGHEIDSADRES VAN APPLIKANT:**

Pharma Dynamics (Edms) Bpk.  
F02 Grapevine House,  
Steenberg Office Park,  
Westlake,  
7945

**DATUM VAN PUBLIKASIE VAN HIERDIE VOUBILJET:**

24 Maart 1993.